Research programme: neurodegenerative disorders - Bayer Schering Pharma/Neurosciences Victoria

Drug Profile

Research programme: neurodegenerative disorders - Bayer Schering Pharma/Neurosciences Victoria

Latest Information Update: 24 Mar 2010

Price : $50

At a glance

  • Originator Bayer Schering Pharma; Neurosciences Victoria
  • Class Imaging agents
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Neurological disorders

Most Recent Events

  • 29 Dec 2006 Schering AG is now called Bayer Schering Pharma AG
  • 03 Jul 2002 Preclinical trials in Neurological disorders in Germany (unspecified route)
  • 03 Jul 2002 Preclinical trials in Neurological disorders in Australia (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top